Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $19.00 Consensus Target Price from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $19.00.

A number of analysts have weighed in on LXEO shares. Raymond James Financial initiated coverage on Lexeo Therapeutics in a report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price target for the company. Chardan Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, January 13th. Oppenheimer restated an “outperform” rating and set a $20.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. HC Wainwright decreased their target price on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Finally, Cantor Fitzgerald assumed coverage on Lexeo Therapeutics in a report on Monday, December 1st. They issued an “overweight” rating and a $19.00 target price for the company.

Lexeo Therapeutics Stock Up 0.5%

Shares of NASDAQ LXEO opened at $6.66 on Friday. The company has a market capitalization of $486.11 million, a PE ratio of -2.47 and a beta of 1.78. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $10.99. The firm has a fifty day simple moving average of $7.35 and a 200 day simple moving average of $7.90.

Insider Activity at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 10,173 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total transaction of $64,903.74. Following the completion of the sale, the chief executive officer owned 392,483 shares of the company’s stock, valued at $2,504,041.54. This trade represents a 2.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of LXEO. Allworth Financial LP grew its holdings in Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after purchasing an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Lexeo Therapeutics during the fourth quarter valued at about $37,000. California State Teachers Retirement System boosted its position in shares of Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC bought a new position in shares of Lexeo Therapeutics during the 2nd quarter worth about $50,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.